Angiogenesis plays a pivotal role in the development and progression of tumors and it represents a crucial target for therapeutic strategies. Until now, regulatory agencies approved antiangiogenic agents targeting the VEGF and multi-target agents carrying antiangiogenic and anti-proliferative effects. They often provide only a modest survival benefit and their role in clinical practice is debated. The limited efficacy may be partially explained by the complexity of the molecular background of angiogenic processes, composed of several pathways interacting with both tumor cells and the microenvironment.

The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives

Calvetti, Lorenzo;PILOTTO, Sara;Carbognin, Luisa;Ferrara, Roberto;CACCESE, MARIO;TORTORA, GIAMPAOLO;Bria, Emilio
2015

Abstract

Angiogenesis plays a pivotal role in the development and progression of tumors and it represents a crucial target for therapeutic strategies. Until now, regulatory agencies approved antiangiogenic agents targeting the VEGF and multi-target agents carrying antiangiogenic and anti-proliferative effects. They often provide only a modest survival benefit and their role in clinical practice is debated. The limited efficacy may be partially explained by the complexity of the molecular background of angiogenic processes, composed of several pathways interacting with both tumor cells and the microenvironment.
angiogenesis; gastric cancer; ramucirumab; review; Angiogenesis Inhibitors; Antibodies, Monoclonal; Breast Neoplasms; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Neovascularization, Pathologic; Vascular Endothelial Growth Factor Receptor-2
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/953662
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? ND
social impact